Table 4.
Complications and outcomes during pretransplant therapy.
| Variables | VTD (n = 62) | VCD (n = 43) | p-Value * |
|---|---|---|---|
| Drug complications | |||
| Neutropenia | 11 (17.7%) | 15 (34.9%) | 0.045 |
| Thrombocytopenia | 3 (4.8%) | 5 (11.6%) | 0.197 |
| Anemia | 4 (6.5%) | 10 (22.7%) | 0.012 |
| Pancytopenia | 4 (6.5%) | 4 (9.3%) | 0.588 |
| Neuropathy | 11 (17.7%) | 3 (7.0%) | 0.110 |
| Kidney damage | 5 (8.1%) | 11 (25.6%) | 0.014 |
| Elevated liver enzymes | 13 (21.0%) | 10 (22.7%) | 0.780 |
| Others | 5 (8.1%) | 5 (11.6%) | 0.540 |
| Disease-related complications | |||
| Infection | 18 (29.0%) | 11 (25.6%) | 0.697 |
| Fractures | 4 (6.5%) | 2 (4.7%) | 0.695 |
| Anemia | 18 (29.0%) | 13 (30.2%) | 0.894 |
| Reduced kidney function | 32 (51.6%) | 12 (27.9%) | 0.015 |
| Others | 5 (8.1%) | 2 (4.7%) | 0.490 |
| Treatment response | 0.033 | ||
| CR | 11 (17.7%) | 16 (37.2%) | |
| PR | 12 (19.4%) | 9 (20.9%) | |
| SD | 12 (19.4%) | 10 (23.3%) | |
| PS | 27 (43.5%) | 8 (18.6%) | |
| ICU admissions | 4 (6.5%) | 9 (20.9%) | 0.026 |
| Death | 3 (4.8%) | 4 (9.3%) | 0.367 |
| Mean progression-free survival, (months) | 31.6 ± 9.9 | 27.2 ± 10.4 | 0.030 |
| Maintenance after ASCT | Thalidomide (n = 11) | Lenalidomide (n = 16) | |
| Mean progression-free survival, (months) | 35.5 ± 10.3 | 46.1 ± 11.8 | 0.023 |
* Chi-squared or Fisher’s exact test; ICU—intensive care unit; CR—complete response; PR—partial response; SD—stable disease; PS—progression; ASCT—autologous stem cell transplant.